Ansbert Gadicke
QuietNamed in filings at MPM BioVenturesOn the current fund
- Board seats filed
- 7
Named in filings at MPM BioVenturesOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Reunion Neuroscience | Biotech & pharma | January 2024 | None on file |
| NextPoint Therapeutics | Biotech & pharma | December 2022 | None on file |
| Orna Therapeutics Holdings | Biotech & pharma | August 2022 | Vida Ventures |
| iTeos Therapeutics | Biotech & pharma | March 2020 | None on file |
| ViraCyte | Biotech & pharma | September 2018 | None on file |
| Clinical Ink | Enterprise software | March 2015 | None on file |
| CHIASMA | Biotech & pharma | December 2014 | Abingworth Bioventures |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Ansbert Gadicke on the board, based on 7 filed seats with a verified or cited source.